EZR and breast carcinoma: In addition, it has been shown that palmitoylation of two cysteine residues in CD44, at positions 286 and 295, in breast cancer cells can result in high affinity of CD44 for cholesterol‐rich lipid rafts, thus limiting the distribution of CD44 to lipid rafts, restricting the binding of CD44 with promigratory binding partners, such as ezrin, and thus reducing the metastatic spread of breast cancer.110